Biolojic Design Enters into Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany in oncology and immunology
Nektar Therapeutics Has Exercised Its License Option to Develop Biolojic Design's AI-Designed Antibody Targeting TNFR2 in Immunology
Teva and Biolojic Design Announce Exclusive License Agreement